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Background: Anal fissure (AF) is regarded as a common problem, but there are no published epidemiologic data,
nor information on current treatment. The purpose of this study was to examine the incidence, associated
comorbidities, and treatment of AF in a population-based cohort.
Methods: We conducted a retrospective analysis of all persons who were enrolled in one large regional managed
care system and treated for AF during calendar years 2005–2011. All persons aged 6 years or older who had a
clinic, hospitalization, or surgical procedure associated with AF were identified from utilization data. To identify
comorbidities associated with AF, each case was matched by age and gender to 3 controls.
Results: There were 1,243 AF cases, including 721 (58%) females and 522 (42%) males; 150 (12%) of the cases
occurred in children aged 6–17 years. The overall annual incidence was 0.11% (1.1 cases per 1000 person-years), but
ranged widely by age [0.05% in patients 6–17 years to 0.18% in patients 25–34 years]. The incidence also varied by sex,
and was significantly higher among females 12–24 years, and among males 55–64 years (P < 0.001). Comorbidities
associated with AF included chronic constipation (prevalence 14.2% vs 3.6%), hypothyroidism (14.7% vs 10.4%), obesity
(13.0% vs 7.7%), and solid tumors without metastasis (5.2% vs 3.7%) (P < 0.001 for all comparisons). A total of 448 were
dispensed a topical prescription medication, 31 had botulinum toxin injection, and only 13 had lateral internal
sphincterotomy.
Conclusions: AF is a common clinical problem, and the incidence varies substantially by age and sex. Constipation,
obesity, and hypothyroidism are associated comorbidities. Most patients are prescribed topical treatments, although it
appears that many prescriptions are never filled. Surgical interventions for AF including botulinum toxin and lateral
internal sphincterotomy are uncommon.
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An anal fissure (AF) is a small break or tear in the skin
of the anal canal, which typically runs from below the
dentate line to the anal verge, and is usually situated in
the posterior midline [1,2]. AF causes severe pain and
bleeding with bowel movements, and is associated with
spasm of the internal anal sphincter which may lead to
reduction of blood flow and delayed healing [2]. Most
AF are minor and thought to heal spontaneously, but
those that are still symptomatic after 4 to 6 weeks are
often referred to as chronic AF [1,2].* Correspondence: dmapel@comcast.net
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regard AF as a common problem in adults and children
[3,4], but data on the epidemiology of this disease are very
rare [5]. In a search of the PubMed database using the key
words ‘anal fissure’ and ‘epidemiology’, ‘incidence’, or
‘prevalence’, we could not find any articles published
within the last 30 years with population-based data on the
incidence of AF.
Although the pathogenesis of AF is still uncertain, it is
thought that most fissures are initiated by direct trauma
from passage of hard stools or diarrhea [1-3]. However,
in one review of the etiology of AF only 25% of patients
with AF had chronic constipation [6]. In a prospective
study of 165 women in the last three months of pregnancy
and first 10 weeks post-partum, only 2 had AF beforetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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ring more than 2 weeks after the delivery [7]. The finding
of multiple fissures or AF in an unusual lateral position
can be associated with Crohn’s disease, ulcerative colitis,
HIV infection, neoplasia, syphilis, and tuberculosis [8].
Lateral internal sphincterotomy (LIS), accomplished
by a radial incision in the anoderm followed by division
of the internal sphincter muscles, has long been regarded
as the surgical procedure of choice for AF [1]. Surgical
interventions have had consistently higher success rates
(approximately 89%) than any form of medical therapy,
but are expensive and have a substantial risk of long-term
anal incontinence [9,10]. Over the last three decades sev-
eral topical or injected medications have been proposed as
pharmacological or ‘chemical sphincterotomy’ alternatives
to surgery [1,2,9]. Topical agents that relax the internal
anal sphincter and increase blood flow to the affected
area, such as nitroglycerin ointments or calcium channel
blockers including diltiazem or nifedipine, have been
proven in randomized placebo-controlled trials to be
effective in reducing healing time and success rates [11-18].
Other treatments such as botulinim toxin injections that
directly block anal sphincter hypertonia are marginally
better than placebo in meta-analyses of current random-
ized trials, but success appears to be highly variable [9].
Most recent reviews on AF management, plus the current
guidelines of several international societies of colon and
rectal surgeons, acknowledge that while LIS is the ‘gold
standard’ for AF treatment in terms of treatment success,
it is reasonable to offer most patients medical treatments
as first-line therapy [19]. How often these recommenda-
tions are followed among persons treated in the general
population is not currently described in the medical
literature.
The purpose of this study was to describe the epidemi-
ology, risk factors, associated comorbidities, and current
treatment of AF in a population-based cohort. To accom-
plish this, we performed a retrospective analysis of all
persons aged 6 years and older who were diagnosed
with AF and who were enrolled in a large integrated
medical system in the Southwestern United States.
Methods
The patients included in this retrospective historical cohort
analysis were enrolled in one regional healthcare system
based in Albuquerque, New Mexico, USA. Utilization data
from this system are routinely de-identified and collected
into an electronic database maintained by the Lovelace
Clinic Foundation, a non-profit organization that special-
izes in health services research. All healthcare utilization
and outpatient pharmacy fills for all members are cap-
tured by this database, regardless of where the utilization
occurs. The system had an average annual enrollment of
over 220,000 during the 7-year study period (January 1,2005 and December 31, 2011). This project was ap-
proved and monitored by an independent human
research review board (Ethical and Independent Review
Services® 12072-01c).
For study inclusion, patients were required to have
one or more visits or procedures during the study period
associated with an ICD-9 diagnosis code of 565.0 (anal
fissure). The date of the first visit associated with a 565.0
diagnostic code is referred to as the date of first diagnosis;
these patients are referred to as incident AF cases. Patients
may be an incident AF case only one time, and all of their
subsequent visits are considered evidence of either con-
tinuation of the initial lesion or recurrence of AF. Persons
who had follow-up visits for AF 12 weeks or more after
the initial visit were defined as having chronic or recurrent
AF. All cases had to be 6 years of age or older at the time
of diagnosis for inclusion in the study.
The incidence of AF during the study period was cal-
culated by comparing the number of incident AF cases
diagnosed to the total person-years at risk within each
age, sex, or ethnicity category. Patients could enroll or
disenroll from the health plan in the middle of a calen-
dar year, or otherwise not have a full 12 months of time
at risk of developing AF, which creates a risk of bias that
might be introduced by variable enrollment periods.
Therefore, to reduce this bias, the incidence in person-
years was calculated by comparing the number of AF
cases occurring during a calendar year by the total
person-months of enrollment during that period divided
by 12.
Case–control matching was used to help identify
comorbidities associated with anal fissures. Each anal
fissure case was matched to 3 similar patients who did not
have anal fissure. The matching criteria included:
 age at the time of diagnosis/index date [±two years]
 sex
 encounter type [ambulatory (clinic) visit, Emergency
Department, or inpatient]
 diagnosis month [+/− 6 months]
 enrolled months after index date [+/− 2 months]
The Elixhauser system for capturing prognostically
significant comorbidities was used for both the case and
control groups [20]. To be included in the case–control
analysis, patients had to have 12 months of continuous
enrollment data available just prior to the first AF diag-
nosis date.
The prescription drugs are identified in the database by
National Drug Code (NDC) identifiers, and all prescription
drugs dispensed within one week of the initial diagnosis
were captured for each AF patient. Procedures associated
with AF were identified using Current Procedural Termin-
ology (CPT) codes.
Table 1 Demographic characteristics of the anal fissure
study cohort
Male Female
Description N % N %
Sex (row%) 522 42.0% 721 58.0%
Mean age (years)* 46.6 40.9
Age categories (column%)
Age 6 - 11 34 6.5% 48 6.7%
Age 12 - 17 20 3.8% 48 6.7%
Age 18 - 24 38 7.3% 107 14.8%
Age 25 - 34 63 12.1% 134 18.6%
Age 35 - 44 81 15.5% 86 11.9%
Age 45 - 54 83 15.9% 101 14.0%
Age 55 - 64 94 18.0% 82 11.4%
Age 65+ 109 20.9% 115 16.0%
Ethnicity
Hispanic (row%) 249 42.9% 331 57.1%
Mean age (years) 44.6 38.1
Non-Hispanic (row%) 273 41.2% 390 58.8%
Mean age (years) 48.3 43.3
*Mean difference significant P < 0.001.
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ture prescription medications that have to be formulated
by compounding pharmacists because compounded medi-
cations do not have specific NDC codes and because these
products are not a part of the insurance benefit covered
by the health plan. The commercial 0.4% product (Rectiv®)
was not available during the study period. However,
discussions with local pharmacists confirmed that some
AF patients during the study period were prescribed the
2% nitroglycerin ointment with instructions to either pro-
vide it to the compounding pharmacist to dilute to 0.2%
or 0.4%, or for the patient to mix it with topical lidocaine
or other products prior to application. Therefore, we as-
sumed that all prescriptions for the topical 2% nitrogly-
cerin product dispensed at the time of an AF visit were
intended for the treatment of AF. All drugs that were dis-
pensed to cases within one week of the index date, and all
procedures associated with AF diagnoses, were captured
and cross-referenced to find any patients with AF who
may have been missed by the initial search.
To examine the frequency of initial treatment with
compounded agents, and to capture the physician rec-
ommendations for non-prescription drug treatments, we
conducted a medical record review and abstraction. A
majority of the patients during the study period received
their primary and specialty care through physicians affili-
ated with ABQ Health Partners® (ABQHP), which in
2008 began implementing an electronic medical record
(EMR). For the medical record abstraction, all AF cases
included in the ABQHP’s EMR system in the last two
years of the study period were identified, and any infor-
mation related to treatment for AF reviewed. A data
abstraction instrument and protocol were developed
by an experienced professional medical record abstractor,
and the specific items to be abstracted verified by our sur-
gical consultants.
Statistical methods
All categorical variables were compared using Chi-square
statistics with the Yates correction. Normally distributed
means were compared using the Student’s t-test, and
non-parametric continuous data were compared using
the Wilcoxon rank-sum test. McNemar’s test was used
for the case–control comparisons. All data processing
and analyses were conducted using SAS® software, and
the medical record abstraction data were compiled using
Microsoft Access®.
Results
A total of 1243 persons met all study inclusion criteria
(Table 1). More women (N = 721, 58% of cohort) were
diagnosed with AF than men. This health system enrolls
a higher proportion of women overall (55.8% during the
study period), and after calculation of the incidence ofAF by person-years at risk, the overall difference in AF
by sex did not reach statistical significance (p = 0.08)
(Table 2). However, there were several important differ-
ences between men and women by age strata (Figure 1
and Table 2). Women from 12–24 had significantly
higher incidence of AF than males at those age, while
men age 55–64 had significantly higher AF incidence
than women. Accordingly, the mean age among women
with AF was 40.9 years and among men was 46.6 years
(p < 0.001).
Persons of Hispanic heritage comprised 46.6% of the
overall cohort, which is consistent with the demographics
of the regional population and this health system (Table 1).
Overall, there was no difference between Hispanic and
Non-Hispanic persons in the incidence of AF (1.09 and
1.10 cases per 1000 person-years, respectively). However,
there was a higher incidence of AF among Hispanic
persons in the 55–64 age group (1.69 versus 1.08 cases
per 1000 person-years; p < 0.01), mostly due to a slightly
higher occurrence among men (2.00 cases per 1000
person-years among Hispanic men age 55–64 years).
The case–control comparison of comorbid conditions
identified several factors associated with AF (Table 3).
As expected, the largest proportional difference was in
diagnosed chronic constipation, which was more than
3 times higher in cases (14.0% versus 3.6%, p <0.001).
Hypothyroidism (14.7% versus 10.4%, p <0.001) and
obesity were also common and substantially increased
among cases. Solid tumors without metastasis and weight
Table 2 Incidence of anal fissure (cases/1000 person-










6-11 0.49 *** 0.44 0.54
12-17 0.52 *** 0.24 0.80 ***
18-24 1.47 0.96 1.78 ***
25-34 1.76 1.76 1.76
35-44 1.46 1.62 1.34
45-54 1.25 ** 1.29 1.22
55-64 1.31 * 1.51 1.13 ***
65+ 1.01 *** 1.17 0.88
Total 1.10 1.04 1.14
†Difference between 25–34 group and starred age groups significant at: *P <
0.01; **P < 0.001; ***P < 0.0001.
††Difference between sexes within this age group significant at: ***P < 0.0001.
Table 3 Comparison of chronic comorbidities among anal
fissure cases versus age- and sex-matched controls
(1 to 3 matching)
Cases Controls
Description N % N % P-value
No. of patients* (% of cohort) 1062 3186
Elixhauser comorbidities:
AIDS 5 0.5% 7 0.2% 0.182
Alcohol abuse 24 2.3% 97 3.0% 0.183
Chronic blood loss anemia 12 1.1% 38 1.2% 0.870
Coagulopathy 14 1.3% 43 1.4% 0.939
Congestive heart failure 27 2.5% 93 2.9% 0.521
Constipation 149 14.0% 114 3.6% <0.001
Deficiency anemias 87 8.2% 227 7.1% 0.250
Depression 149 14.0% 387 12.2% 0.110
Diabetes (no chr complication) 147 13.8% 402 12.6% 0.303
Diabetes (w/chr complications) 30 2.8% 117 3.7% 0.191
Drug abuse 29 2.7% 112 3.5% 0.216
Fluid and electrolyte disorders 56 5.3% 168 5.3% 1.000
Hypertension 344 32.4% 959 30.1% 0.161
Hypothyroidism 156 14.7% 330 10.4% <0.001
Liver disease 34 3.2% 84 2.6% 0.332
Lymphoma 8 0.8% 17 0.5% 0.418
Metastatic cancer 12 1.1% 23 0.7% 0.203
Obesity 138 13.0% 246 7.7% <0.001
Other neurological disorders 48 4.5% 161 5.1% 0.486
Paralysis 7 0.7% 24 0.8% 0.755
Peripheral vascular disease 37 3.5% 109 3.4% 0.923
Pregnancy 72 6.8% 276 8.7% 0.053
Psychoses 99 9.3% 256 8.0% 0.189
Pulmonary circulation disease 23 2.2% 60 1.9% 0.565
Renal failure 29 2.7% 84 2.6% 0.869
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significance. Pregnancy was negatively associated with AF,
which is the opposite of what was anticipated, but likely
due to the preference among obstetricians in this system
to use ICD-9 diagnosis code 664.6 (anal sphincter tear
complicating delivery) instead of ICD-9 565 (anal fissure).
Note that conditions that might contraindicate use of
topical vasodilators, such as pulmonary vascular disease,
are uncommon.
Of the 1243 patients in the cohort, 1109 (89.2%) were
diagnosed during an ambulatory visit, 23 (1.8%) during a
hospitalization, and the remaining 111 (8.9%) were diag-
nosed during a procedure such as colonoscopy. Among the
ambulatory AF cases, 120 persons were initially diagnosed
during an emergency department visit. Approximately two-
thirds of the ambulatory AF cases (746 patients; 67.3%) did
not have a billed follow-up visit after the initial diagnosis.
Of those who did have a follow-up visit, 182 patients













Figure 1 Incidence of anal fissure (cases per 1000 persons per
year) by sex and age group.
Rheumatoid arth./ col. vasc. dz 37 3.5% 120 3.8% 0.673
Solid tumor - no metastasis 55 5.2% 118 3.7% 0.035
Valvular disease 30 2.8% 111 3.5% 0.299
Weight loss 40 3.8% 54 1.7% <0.001
Any Elixhauser diagnosis 741 69.8% 2091 65.6% 0.013
*The case–control comparison is limited to adults age 18 and older because
the Elixhauser comorbidity classification system is not validated in children.73 (6.6%) had two follow-up visits, and the remaining
108 (9.7%) required three or more follow-up visits.
Among the entire study cohort, 177 AF patients (14.2%)
had a follow-up visit 12 weeks or more after the initial
visit, indicating that they had chronic or recurrent AF.
At the time of the initial diagnosis, pharmacy utilization
records indicate that 436 patients had one or more
prescriptions filled for either a topical corticosteroid,
lidocaine gel, nitroglycerine 2% ointment, diltiazem, or
Table 5 Over-the-counter (OTC) medications and
non-medication treatments recommended at any time
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the most common prescriptions filled (300 patients),
followed by lidocaine (190 patients), nitroglycerine 2%
ointment (93 patients), and diltiazem (2 patients). Most
(346) patients initially filled only one type of treatment,
and among those getting multiple prescription fills, lido-
caine and nitroglycerine was the most commonly pre-
scribed combination (48 patients).
Only 3 patients had a procedure for AF prior to getting
a medical prescription therapy: one had a botulinim toxin
(BT) injection as their initial treatment, and two persons
had LIS as their initial treatment. All of the others who
were treated with BT injections and 4 of the patients who
had LIS waited at least 12 weeks after their initial diagno-
sis before getting their procedure. Of the 31 persons who
had BT injections, 11 required at least one subsequent
additional BT treatment. Of the 13 patients who had a
LIS, only one required a second LIS procedure.
Medical record abstraction was accomplished for 179
patients who were diagnosed in the last 2 years of the
study period and who had any documentation of their
AF evaluation available in the EMR. The majority (54.8%)
were initially diagnosed by a surgeon, but 61 patients
(34.1%) were diagnosed by a primary care physician, and 8
AF patients (4.5%) were diagnosed by a gastroenterologist.
Recommended treatments and prescriptions that were
documented in the records are listed in Table 4. A total
of 115 patients (64.2%) were recommended at least one
prescription medication at the time of the initial diagno-
sis, which is substantially higher than the percent of
ambulatory patients documented to have a prescription
fill (39.3%). Compounded 0.4% nitroglycerine, which
cannot be identified as dispensed in the utilization data-
base, was a common initial treatment (21.8%). No patient
was prescribed a compounded ointment containing a
calcium channel blocker at the initial visit, but five pa-
tients (4 nifedipine, 1 diltiazem) were prescribed one on
a follow-up visit.
Documentation of recommendations for non-prescription
(over-the-counter) medications was recorded in the
medical records of 65 patients (36.3%) either on theTable 4 Type of medication prescribed at time of initial
diagnosis*
N (% of abstracted)
Nitroglycerine 0.4% (compounded) 39 (21.8%)
Nitroglycerine 2% (topical ointment) 29 (16.2%)
Lidocaine (topical ointment or gel) 70 (39.1%)
Corticosteroid (topical - all forms) 37 (20.1%)
Cyclobenzaprine tablets 7 (3.9%)
Topical antibiotic 4 (2.2%)
Diphenhydramine cream 2 (1.1%)
*Results from 179 patients with medical record abstraction.initial visit or during follow-up (Table 5). The majority
(119 patients; 66.5%) of those abstracted also had non-
medication recommendations such as sitz baths, diet-
ary modifications, and adequate fluid intake.Discussion
Most surgeons and published expert opinions describe
AF as ‘common’, but systematically collected incidence
data on AF are not available. Extrapolation of the incidence
rates in this cohort to the 2010 US census population
(292.7 million aged ≥6 years), with adjustment by age and
sex, indicates that there are approximately 342,000 new AF
cases diagnosed in the US each year. This is similar to the
annual incidence of appendectomies in the US (approxi-
mately 280,000 cases per year, or 0.7 to 1.7 cases per 1000
person-years depending on age) and in Ontario, Canada
(approximately 0.75 appendectomies per thousand person-
years) [21-25]. The overall incidence of 1.1 per 1000
person-years translates to an average life time risk of 7.8%,
and thus AF is indeed a common problem.
Our analysis reveals some important details about
the variation in AF incidence by age and sex. Women
had a higher overall incidence (1.14 cases per thousand
person-years), than men (1.04 cases per thousand
person-years), but the difference did not reach statis-
tical significance. Among women the peak incidence
occurred during adolescence and young adulthood, but
among men the incidence was highest during middle
age. We had anticipated that women of child-bearing
age would have a higher incidence of AF based on pre-
viously published studies among pregnant women, but
we found that in this health system pregnancy-related
fissures were more likely to be diagnosed and coded as
anal tears (ICD-9 diagnosis code 664.6). This is probably a
reasonable distinction since most delivery related tears are
anterior and a result of perineal injury from childbirth,
while most AF are posterior and thought to be due toduring the study period*
N (% of abstracted)
Stool softeners 30 (16.8%)
Laxatives 39 (21.8%)
OTC topical pain relievers (e.g., Preparation
H®, Anusol®)
11 ( 6.1%)
Total patients with a documented OTC
medication recommendation
65 (36.3%)
Specific diet recommendations (e.g., increased
fiber in diet)
96 (53.6%)
Total with ≥1 non-pharmaceutical treatment
recommendations
119 (66.5%)
*Results from 179 patients with medical record abstraction.
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retrospective survey we can only speculate about the
reasons for the fluctuations in incidence by age and
gender. However, the case–control analysis confirms a
strong association between constipation and AF, and
between other conditions associated with constipation
(e.g., hypothyroidism, obesity). The variation in AF in-
cidence by age and sex also tends to follow changes in
constipation incidence by age and sex [26].
There are important limitations to this study that
should be considered. First, we relied on ICD-9 coding
to identify AF cases, which introduces the potential for
misclassification errors. We found in the chart review of
179 cases that a physician had documented a diagnosis
AF in every case, so the ICD-9 code for AF (565.0) was
specific, but we do not know the sensitivity of this case
identification system because we are not able to go back
and reexamine every potential AF patient. Other research
suggests that the accuracy of AF diagnosis depends greatly
on the skills of the examining physician. One study from
Spain demonstrated that surgeons can identify AF with
very high reliability, but primary care providers were
much less likely to correctly identify an AF lesion [27].
Another limitation is that the population demographics
in the study area are substantially different than those in
other parts of the US. Although we did not find a substan-
tial difference between Hispanics and Non-Hispanics, with
the possible exception of middle aged men, it is possible
that other ethnic or racial groups have a different risk
for AF.
Our risk estimates for the comorbidities associated with
AF are likely to be biased by the fact that patients with AF
were very likely to be asked about constipation and other
gastrointestinal problems, while the controls were less likely
to be asked about constipation because they were being
seen for any complaint other than AF. In fact, the preva-
lence of constipation in our control population was much
lower than the estimates from population surveys [26].
Finally, it is very difficult to capture utilization of com-
pounded prescription drugs that are not paid for by the
insurance plan. Our medical record review confirmed
that substantial numbers of AF cases (64.2%) were given
prescriptions for compounded nitroglycerine and calcium
channel blockers, but our review of the pharmacy
utilization data indicates that actual prescription fills
were much lower than this. For example, 16.2% of patients
in the chart review were given a prescription for nitrogly-
cerin 2% cream, but only 7.5% of patients in the overall
cohort actually had a prescription for nitroglycerine 2%
cream filled. We suspect that many of these prescriptions
were never filled because compounded preparations are
not available in all pharmacies, and because many patients
find their high cost unaffordable and not covered by their
insurance benefit.Conclusions
We have demonstrated that AF is a problem that many
persons of all ages suffer from, and something that most
surgeons and many primary care providers will be asked
to diagnose and treat. The fluctuations in incidence and
the associated risk factors suggest areas that could be
further investigated for better understanding of the patho-
genesis and prevention of AF. There are also some aspects
of AF treatment that could also be improved. As new
products for AF treatment become available, we anticipate
that education and investigations into clinical management
will increase, and hopefully more physicians will be able to
effectively diagnose and manage AF patients.
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